CN113861008B - Large bud rosin diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation - Google Patents
Large bud rosin diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation Download PDFInfo
- Publication number
- CN113861008B CN113861008B CN202111051450.XA CN202111051450A CN113861008B CN 113861008 B CN113861008 B CN 113861008B CN 202111051450 A CN202111051450 A CN 202111051450A CN 113861008 B CN113861008 B CN 113861008B
- Authority
- CN
- China
- Prior art keywords
- petroleum ether
- gradient elution
- fractions
- ethyl acetate
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/46—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of separation and purification of schizonepeta makino, in particular to a rosin diterpene with a large bract, a preparation method thereof and application thereof in preparing anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation. The invention discloses a compound 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isophthaloyl-1, 4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) for the first time, and in-vitro anti-inflammatory and antibacterial pharmacodynamics experiments are carried out on the compound, the experiment shows that the compound has stronger inhibition effect on RAW 264.7 cells, staphylococcus aureus and escherichia coli, so that the compound can be used for preparing anti-inflammatory and antibacterial drugs or/and health care products for preventing and treating inflammation and antibacterial.
Description
Technical Field
The invention relates to the technical field of separation and purification of schizonepeta majora, in particular to a rosin diterpene with 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthene-1-carbaldehyde (nepetabrate B), a preparation method thereof and application thereof in preparing anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation.
Background
Herba Schizonepetae Nepeta bracteata Benth is a Nepeta plant of Labiatae, and is mainly distributed in the countries such as Pakistan, nepal, iran, etc., with Uygur name of "Zaofa", which is commonly known as Shenxiang herb, and has wide clinical application, mainly imported. The whole herb is used as a medicine, has faint scent of qi, light taste and slight dampness, enters lung and liver channels, has the effects of relieving cough and asthma, clearing heat and promoting diuresis, and is clinically used for treating symptoms such as tracheitis, cough and asthma, cold and fever, difficult urination and the like. In addition, the schizonepeta herb has the characteristics of easy source, low cost, reliable clinical curative effect, small toxic and side effects and the like. So far, the focus of research on schizonepeta makino and basic theoretical research are not seen, modern pharmacology shows that the extract has remarkable anti-inflammatory and antibacterial activities, but related research on chemical components is not carried out yet, and the schizonepeta makino is a species which can treat respiratory diseases well, so that the schizonepeta makino has been paid attention to in recent years.
The drug effect of the schizonepeta majora is mainly derived from terpenoid compounds, including monoterpenes and diterpenoid compounds, wherein the diterpenoid components of the dominant component have good anti-inflammatory and antibacterial activities, so that the diterpenoid monomer compounds of the schizonepeta majora are developed and utilized, the potential medicinal value of the schizonepeta majora is further excavated, the structure and physical and chemical properties of the monomer compounds of the schizonepeta majora are determined and characterized, and the schizonepeta majora has important significance in development and utilization of the schizonepeta majora.
Disclosure of Invention
The invention provides 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isophthalene-1, 4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) and a preparation method and application thereof, overcomes the defects of the prior art, and firstly discloses 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isophthalamide-1, 4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) and application thereof in preparing anti-inflammatory and antibacterial drugs or/and preparing anti-inflammatory and antibacterial health care products.
One of the technical schemes of the invention is realized by the following measures: 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B), with chemical structural formula of
The following are further optimizations and/or improvements to one of the above-described inventive solutions:
the preparation method comprises the following steps: crushing schizonepeta makino, adding ethanol, soaking for 3-4 hours at room temperature, heating and reflux-extracting for 3 times at 50-60 ℃ for 1-3 hours each time, combining the reflux extracting solutions each time, decompressing and recovering and concentrating to obtain schizonepeta makino total extractum; dispersing the total extract of schizonepeta makino with water, and extracting with petroleum ether and dichloromethane in sequence to obtain a petroleum ether part and a dichloromethane part; step three, taking petroleum ether part extractum, and obtaining 8 fractions after gradient elution and separation by a silica gel column chromatography, wherein the gradient elution liquid of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is sequentially 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1:1, 1:0; fourthly, separating the 6 th fraction in the 8 fractions by silica gel column chromatography gradient elution to obtain 5 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 20:1, 10:1 and 3: 1. 1:1, 0:1; fifthly, separating the 3 rd fraction in the 5 fractions by silica gel column chromatography gradient elution to obtain 3 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 10:1, 5:1 and 3:1, a step of; and sixthly, eluting, purifying and separating the 3 rd fraction in the 3 obtained fractions by a high performance liquid chromatography gradient, collecting the eluate, and obtaining 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthine-1-carbaldehyde (nepetabrate B) at the 27.0 min.
In the first step, 8ml to 10ml of ethanol is added to each 1g of schizonepeta.
In the sixth step, the eluent of the high performance liquid chromatography gradient elution is a mixed solution of methanol and water, wherein the volume ratio of the methanol to the water is 85:15.
the second technical scheme of the invention is realized by the following measures: a preparation method of 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthene-1-carbaldehyde (nepetabrate B) is carried out according to the following steps: crushing schizonepeta makino, adding ethanol, soaking for 3-4 hours at room temperature, heating and reflux-extracting for 3 times at 50-60 ℃ for 1-3 hours each time, combining the reflux extracting solutions each time, decompressing and recovering and concentrating to obtain schizonepeta makino total extractum; dispersing the total extract of schizonepeta makino with water, and extracting with petroleum ether and dichloromethane in sequence to obtain a petroleum ether part and a dichloromethane part; step three, taking petroleum ether part extractum, and obtaining 8 fractions after gradient elution and separation by a silica gel column chromatography, wherein the gradient elution liquid of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is sequentially 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1:1, 1:0; fourthly, separating the 6 th fraction in the 8 fractions by silica gel column chromatography gradient elution to obtain 5 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 20:1, 10:1 and 3: 1. 1:1, 0:1; fifthly, separating the 3 rd fraction in the 5 fractions by silica gel column chromatography gradient elution to obtain 3 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 10:1, 5:1 and 3:1, a step of; and sixthly, eluting, purifying and separating the 3 rd fraction in the 3 obtained fractions by a high performance liquid chromatography gradient, collecting the eluate, and obtaining 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthine-1-carbaldehyde (nepetabrate B) at the 27.0 min.
The following is a further optimization and/or improvement of the second technical scheme of the invention:
in the first step, 8ml to 10ml of ethanol is added to each 1g of schizonepeta.
In the sixth step, the eluent of the high performance liquid chromatography gradient elution is a mixed solution of methanol and water, wherein the volume ratio of the methanol to the water is 85:15.
the third technical scheme of the invention is realized by the following measures: application of 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) in preparing medicines for preventing inflammation and inhibiting bacteria.
The fourth technical scheme of the invention is realized by the following measures: use of 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) for the preparation of an anti-inflammatory and antibacterial agent.
The fifth technical scheme of the invention is realized by the following measures: 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) is used for preparing health care products for preventing and treating inflammation and inhibiting bacteria.
The invention discloses a compound 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isophthaloyl-1, 4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) for the first time, and experiments on in vitro anti-inflammatory and antibacterial pharmacodynamics are carried out on the compound, so that the compound has strong inhibition effect on RAW 264.7 cells, staphylococcus aureus and escherichia coli, and can be used for preparing anti-inflammatory and antibacterial drugs or/and antibacterial health care products.
Drawings
FIG. 1 is a chemical structure of 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthene-1-carbaldehyde (nepetabrate B) according to the present invention.
FIG. 2 is a schematic diagram of 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthene-1-carbaldehyde (nepetabrate B) according to the present invention 1 H-NMR spectrum.
FIG. 3 is a schematic diagram of 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthene-1-carbaldehyde (nepetabrate B) according to the present invention 13 C-APT spectrogram.
Detailed Description
The present invention is not limited by the following examples, and specific embodiments can be determined according to the technical scheme and practical situations of the present invention. The various chemical reagents and chemical supplies mentioned in the invention are all commonly known and used in the prior art unless specified otherwise; the percentages in the invention are mass percentages unless specified otherwise; the solutions in the invention are aqueous solutions in which the solvent is water unless otherwise specified, for example, the hydrochloric acid solution is hydrochloric acid aqueous solution; the room temperature and the room temperature in the present invention generally refer to temperatures ranging from 15 ℃ to 25 ℃, and are generally defined as 25 ℃.
The invention is further described below with reference to examples:
example 1: the 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyyl-1, 4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) is characterized by the chemical structural formula
Subjecting 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyyl-1, 4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) of example 1 of the present invention to nuclear magnetic resonance hydrogen spectrometry 1 H-NMR) and nuclear magnetic resonance carbon spectrum 13 C-APT).
1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthene-1-carbaldehyde (nepetabrate B) described in this example 1 The H-NMR spectrum is shown in FIG. 2.
The 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthene-1-carbaldehyde (nepetabrate B) described in this example 13 The C-APT spectrum is shown in FIG. 3.
The pattern analysis is carried out on the graphs of the figures 2 and 3, and the peaks of the figures 2 and 3 are attributed to each other, so that the chemical shift and the peak type of carbon and hydrogen in the structure of the compound 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenate-1-carbaldehyde (nepetabrate B) are obtained, and the chemical structural formula of the compound is shown in the figure 1. Wherein, each peak assignment of fig. 2 and 3 is shown in table 1.
Example 2: the 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) is prepared according to the following method: crushing schizonepeta makino, adding ethanol, soaking for 3-4 hours at room temperature, heating and reflux-extracting for 3 times at 50-60 ℃ for 1-3 hours each time, combining the reflux extracting solutions each time, decompressing and recovering and concentrating to obtain schizonepeta makino total extractum; dispersing the total extract of schizonepeta makino with water, and extracting with petroleum ether and dichloromethane in sequence to obtain a petroleum ether part and a dichloromethane part; step three, taking petroleum ether part extractum, and obtaining 8 fractions after gradient elution and separation by a silica gel column chromatography, wherein the gradient elution liquid of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is sequentially 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1:1, 1:0; fourthly, separating the 6 th fraction in the 8 fractions by silica gel column chromatography gradient elution to obtain 5 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 20:1, 10:1 and 3: 1. 1:1, 0:1; fifthly, separating the 3 rd fraction in the 5 fractions by silica gel column chromatography gradient elution to obtain 3 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 10:1, 5:1 and 3:1, a step of; and sixthly, eluting, purifying and separating the 3 rd fraction in the 3 obtained fractions by a high performance liquid chromatography gradient, collecting the eluate, and obtaining 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthine-1-carbaldehyde (nepetabrate B) at the 27.0 min.
Example 3: as an optimization of the above examples, the 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) was prepared as follows: firstly, crushing schizonepeta makino, adding ethanol, soaking for 3 hours or 4 hours at room temperature, heating and reflux-extracting for 3 times at 50 ℃ or 60 ℃ for 1 hour or 3 hours each time, combining reflux extracting solutions each time, decompressing and recovering and concentrating to obtain schizonepeta makino total extractum; dispersing the total extract of schizonepeta makino with water, and extracting with petroleum ether and dichloromethane in sequence to obtain a petroleum ether part and a dichloromethane part; step three, taking petroleum ether part extractum, and obtaining 8 fractions after gradient elution and separation by a silica gel column chromatography, wherein the gradient elution liquid of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is sequentially 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1:1, 1:0; fourthly, separating the 6 th fraction in the 8 fractions by silica gel column chromatography gradient elution to obtain 5 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 20:1, 10:1 and 3: 1. 1:1, 0:1; fifthly, separating the 3 rd fraction in the 5 fractions by silica gel column chromatography gradient elution to obtain 3 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 10:1, 5:1 and 3:1, a step of; and sixthly, eluting, purifying and separating the 3 rd fraction in the 3 obtained fractions by a high performance liquid chromatography gradient, collecting the eluate, and obtaining 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthine-1-carbaldehyde (nepetabrate B) at the 27.0 min.
Example 4: as an optimization of the above examples, in the first step, 8ml to 10ml of ethanol was added per 1g of schizonepeta makino.
Example 5: as an optimization of the above embodiment, in the sixth step, the eluent of the high performance liquid chromatography gradient elution is a mixed solution of methanol and water, wherein the volume ratio of methanol to water is 85:15.
example 6: the application of the 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) in preparing medicaments for preventing inflammation and inhibiting bacteria.
Example 7: the 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) is used for preparing anti-inflammatory and antibacterial drugs.
Example 8: the 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) is used for preparing health care products for preventing and treating inflammation and inhibiting bacteria.
Example 9: the 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) is obtained according to the following method: crushing schizonepeta makino, adding ethanol, soaking for 3 hours at room temperature, heating and reflux-extracting for 3 times at 50 ℃ for 2 hours each time, combining the reflux extracting solutions each time, decompressing and recovering and concentrating to obtain schizonepeta makino total extractum; dispersing the total extract of schizonepeta makino with water, and extracting with petroleum ether and dichloromethane in sequence to obtain a petroleum ether part and a dichloromethane part; step three, taking petroleum ether part extractum, and obtaining 8 fractions after gradient elution and separation by a silica gel column chromatography, wherein the gradient elution liquid of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is sequentially 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1:1, 1:0; fourthly, separating the 6 th fraction in the 8 fractions by silica gel column chromatography gradient elution to obtain 5 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 20:1, 10:1 and 3: 1. 1:1, 0:1; fifthly, separating the 3 rd fraction in the 5 fractions by silica gel column chromatography gradient elution to obtain 3 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 10:1, 5:1 and 3:1, a step of; and sixthly, eluting, purifying and separating the 3 rd fraction in the 3 obtained fractions by a high performance liquid chromatography gradient, collecting the eluate, and obtaining 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthine-1-carbaldehyde (nepetabrate B) at the 27.0 min.
The 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isophthaloyl-1, 4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) obtained in example 9 of the present invention was subjected to in vitro anti-inflammatory and antibacterial pharmacodynamic experiments, which utilized MTT colorimetric method.
Taking 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) as experimental group, aspin (aspirin, anti-inflammatory drug) as control group, setting blank group at the same time, selecting RAW 264.7 cells as experimental group, control group and blank group, taking 6×10 after dilution of culture medium 4 The density of each ml is inoculated in a 96-well plate, 100 mu l of each well is cultured normally in an incubator for 24 hours, and the corresponding medicines are added into each group, so that the final concentration of each group of medicines is respectively 2.5 mu g/ml (1 group), 5 mu g/ml (2 group), 10 mu g/ml (3 group), 20 mu g/ml (4 group) and 40 mu g/ml (5 group), 5 concentrations are set, and 3 compound wells are arranged for each concentration; after 48 hours of incubation, 10. Mu.l of MTT was added to each well for staining; after further culturing for four hours, the stock culture was aspirated, 150. Mu.l of DMSO was added to each well,placing on a shaking table, oscillating at low speed for 10min to dissolve the crystal, detecting optical density value at 570nm wavelength of ELISA, and calculating 50% Inhibition Concentration (IC) according to the optical density value 50 Mu M), optical density value calculating IC 50 The calculation method is a prior known technology. IC of experimental group and control group on RAW 264.7 cells 50 As shown in table 2. As can be seen from the data in Table 2, 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4 a-dimethylphenanthene-1-carbaldehyde (nepetabrate B) of the present invention has a certain inhibition effect on RAW 264.7 cells.
Taking 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) as an experimental group, taking Penicillin (amoxicillin) as a control group, simultaneously setting a blank group, taking staphylococcus aureus and escherichia coli as experimental objects in the experimental group, diluting a sample by a certain multiple with sterile water or DMSO, centrifuging to take 100 mu L of the sample, adding the sample into a hole of an indicator bacteria plate to serve as a bacteriostasis experimental hole, taking a freshly cultured indicator strain, regulating the concentration of a bacterial suspension to 0.5McFarland, uniformly coating the bacterial suspension on the plate, placing the bacterial suspension on the flat plate for culturing for 24 hours or 48 hours at a corresponding temperature, and observing the colony growth condition of each dish. 100 μl of fresh medium was added to the wells as negative control wells and amoxicillin solution as positive control. After dilution of the medium, the culture medium was diluted to 6X 10 4 The density of each ml is inoculated in a 96-well plate, 100 mu l of each well is cultured normally in an incubator for 24 hours, and the corresponding medicines are added into each group, so that the final concentration of each group of medicines is respectively 2.5 mu g/ml (1 group), 5 mu g/ml (2 group), 10 mu g/ml (3 group), 20 mu g/ml (4 group) and 40 mu g/ml (5 group), 5 concentrations are set, and 3 compound wells are arranged for each concentration; after 48 hours of incubation, 10. Mu.l of MTT was added to each well for staining; after further culturing for four hours, the stock culture was aspirated, 150. Mu.l of DMSO was added to each well, the mixture was allowed to oscillate on a shaking table at low speed for 10min to allow the crystals to be sufficiently dissolved, and the optical density value was measured at 570nm wavelength of an ELISA, and 50% Inhibitory Concentration (IC) was calculated from the optical density value 50 Mu M), optical density value calculating IC 50 The calculation method is a prior known technology. Experiment group, control group against staphylococcus aureus and escherichia coliIC 50 As shown in table 3. As can be seen from the data in Table 3, 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) disclosed by the invention has a certain inhibition effect on staphylococcus aureus and escherichia coli.
In summary, the invention discloses the compounds 1,2,3, 4a,9,10 a-octahydro-2-hydroxy-7-isopropyl-1,4a-dimethylphenanthrene-1-carbaldehyde (nepetabrate B) for the first time, and the compounds are subjected to in vitro anti-inflammatory and antibacterial pharmacodynamic experiments, so that the experiments show that the compounds have strong inhibition effects on RAW 264.7 cells, staphylococcus aureus and escherichia coli, and the compounds can be used for preparing anti-inflammatory and antibacterial drugs or/and preparing anti-inflammatory and antibacterial health care products.
The technical characteristics form the embodiment of the invention, have stronger adaptability and implementation effect, and can increase or decrease unnecessary technical characteristics according to actual needs so as to meet the requirements of different situations.
TABLE 1
TABLE 2
TABLE 3 Table 3
Claims (6)
1. A compound is characterized by having a chemical structural formula of
。
2. A process for the preparation of a compound according to claim 1, characterized by the following steps: crushing schizonepeta makino, adding ethanol, soaking for 3-4 hours at room temperature, heating and reflux-extracting for 3 times at 50-60 ℃ for 1-3 hours each time, combining the reflux extracting solutions each time, decompressing and recovering and concentrating to obtain schizonepeta makino total extractum; dispersing the total extract of schizonepeta makino with water, and extracting with petroleum ether and dichloromethane in sequence to obtain a petroleum ether part and a dichloromethane part; step three, taking petroleum ether part extractum, and obtaining 8 fractions after gradient elution and separation by a silica gel column chromatography, wherein the gradient elution liquid of the silica gel column chromatography comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is sequentially 1:0, 100:1 and 50: 1. 25:1, 8:1, 5:1, 1:1, 1:0; fourthly, separating the 6 th fraction in the 8 fractions by silica gel column chromatography gradient elution to obtain 5 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 20:1, 10:1 and 3: 1. 1:1, 0:1; fifthly, separating the 3 rd fraction in the 5 fractions by silica gel column chromatography gradient elution to obtain 3 fractions, wherein the silica gel column chromatography gradient elution comprises petroleum ether and ethyl acetate, and the volume ratio of the petroleum ether to the ethyl acetate is 10:1, 5:1 and 3:1, a step of; and sixthly, eluting, purifying and separating the 3 rd fraction in the 3 obtained fractions by using a high performance liquid chromatography gradient, collecting the eluate, and obtaining the compound at the 27.0 th minute.
3. The method for producing a compound according to claim 2, wherein in the first step, 8ml to 10ml ethanol is added per 1. 1g bud schizonepeta.
4. A method for preparing a compound according to claim 2 or 3, wherein in the sixth step, the eluent of the high performance liquid chromatography gradient elution is a mixed solution of methanol and water, wherein the volume ratio of methanol to water is 85:15.
5. use of a compound according to claim 1 for the preparation of a medicament for the prophylaxis of inflammation of RAW 264.7 cells and for the inhibition of staphylococcus aureus and escherichia coli.
6. Use of a compound according to claim 1 for the preparation of a medicament against RAW 264.7 cell inflammation and against staphylococcus aureus and escherichia coli.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111051450.XA CN113861008B (en) | 2021-09-08 | 2021-09-08 | Large bud rosin diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111051450.XA CN113861008B (en) | 2021-09-08 | 2021-09-08 | Large bud rosin diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113861008A CN113861008A (en) | 2021-12-31 |
| CN113861008B true CN113861008B (en) | 2024-03-12 |
Family
ID=78994887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111051450.XA Active CN113861008B (en) | 2021-09-08 | 2021-09-08 | Large bud rosin diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113861008B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114853610A (en) * | 2022-06-07 | 2022-08-05 | 新疆维吾尔自治区中药民族药研究所 | Preparation method and application of abietane diterpene in schizonepeta bracteata |
| CN115010581A (en) * | 2022-06-07 | 2022-09-06 | 新疆维吾尔自治区中药民族药研究所 | Abietane diterpene in hyssop officinalis and preparation method and application thereof |
| CN114890870A (en) * | 2022-06-07 | 2022-08-12 | 新疆维吾尔自治区中药民族药研究所 | Abietane diterpene in schizonepeta bracteata extract as well as preparation method and application thereof |
| CN114853841A (en) * | 2022-06-07 | 2022-08-05 | 新疆维吾尔自治区中药民族药研究所 | Nepetalactone as well as preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101500937A (en) * | 2006-08-11 | 2009-08-05 | 万能药生物有限公司 | Particles for delivery of active ingredients, process of making and compositions thereof |
| CN102229588A (en) * | 2011-03-25 | 2011-11-02 | 中国人民解放军第二军医大学 | Briarane type diterpenoid compounds with anti-tumor and antibacterial activities and application thereof |
| CN106420919A (en) * | 2016-10-20 | 2017-02-22 | 新疆医科大学 | Preparation method and application of Nepeta bracteatatotal flavonoids |
| KR20170091393A (en) * | 2016-02-01 | 2017-08-09 | 제주대학교 산학협력단 | A composition having anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient |
| CN107298641A (en) * | 2017-06-07 | 2017-10-27 | 新疆维吾尔自治区中药民族药研究所 | The preparation method of gossypol and the preparation method of gossypol acetate |
| CN108503521A (en) * | 2018-02-12 | 2018-09-07 | 新疆维吾尔自治区中药民族药研究所 | Guainane type sequiterpene A and preparation method thereof and as the application for preparing pre- preventing tumor and antitumor drug |
| CN110023278A (en) * | 2016-11-10 | 2019-07-16 | 建明工业 | Method for producing thymoquinone |
-
2021
- 2021-09-08 CN CN202111051450.XA patent/CN113861008B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101500937A (en) * | 2006-08-11 | 2009-08-05 | 万能药生物有限公司 | Particles for delivery of active ingredients, process of making and compositions thereof |
| CN102229588A (en) * | 2011-03-25 | 2011-11-02 | 中国人民解放军第二军医大学 | Briarane type diterpenoid compounds with anti-tumor and antibacterial activities and application thereof |
| KR20170091393A (en) * | 2016-02-01 | 2017-08-09 | 제주대학교 산학협력단 | A composition having anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient |
| CN106420919A (en) * | 2016-10-20 | 2017-02-22 | 新疆医科大学 | Preparation method and application of Nepeta bracteatatotal flavonoids |
| CN110023278A (en) * | 2016-11-10 | 2019-07-16 | 建明工业 | Method for producing thymoquinone |
| CN107298641A (en) * | 2017-06-07 | 2017-10-27 | 新疆维吾尔自治区中药民族药研究所 | The preparation method of gossypol and the preparation method of gossypol acetate |
| CN108503521A (en) * | 2018-02-12 | 2018-09-07 | 新疆维吾尔自治区中药民族药研究所 | Guainane type sequiterpene A and preparation method thereof and as the application for preparing pre- preventing tumor and antitumor drug |
Non-Patent Citations (1)
| Title |
|---|
| Anti HHV-1 and HHV-2 activity in vitro of abietic and dehydroabietic acid derivatives;Lee Solbay Agudelo Gómez等;《Pharmacologyonline》(第1期);第36-42页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113861008A (en) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113861008B (en) | Large bud rosin diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation | |
| CN113831245B (en) | Diterpene in schizonepeta tenuifolia extract, and preparation method and application thereof | |
| CN113861126B (en) | Highly oxidized diterpene, preparation method thereof and application thereof in preparation of anti-inflammatory and antibacterial drugs for preventing or/and treating inflammation | |
| CN114044734B (en) | Rosin alkane diterpene and preparation method and application thereof | |
| CN113943211B (en) | Diterpene in Uighur medicinal material, preparation method thereof and application of diterpene in preparation of anti-inflammatory and antibacterial medicines for preventing or/and treating inflammation | |
| CN108503521B (en) | Guaiane type sesquiterpene A, its preparation method and application in preparing medicine for preventing tumor and resisting tumor | |
| CN111217706B (en) | Marine-derived polyketide hypoxone A, its preparation method and application in the preparation of anti-inflammatory drugs | |
| CN115010589B (en) | Large bud abietane diterpenoid component in vanilla extract, and preparation method and application thereof | |
| CN115181083B (en) | Preparation method of compound Cyophiobiolins A-B and its application in preparing anti-inflammatory drugs | |
| CN116836139A (en) | Pyrone compound based on endophytic fungus source and preparation method and application thereof | |
| CN109776561A (en) | Compounds cytorhizins B and C, their preparation method and application in the preparation of antitumor drugs | |
| CN116354917A (en) | Dendrobium aureosallowii endophytic fungus chromone compound DWT001 and preparation and application thereof | |
| CN109369399B (en) | 1, 3-O-diferulate-2-methoxy propylene glycol and preparation method and application thereof | |
| CN114890870A (en) | Abietane diterpene in schizonepeta bracteata extract as well as preparation method and application thereof | |
| CN109651233B (en) | Alkaloid compound, and method for extracting and separating alkaloid compound from dendrobium clavatum and application of alkaloid compound | |
| CN108299178B (en) | Guaiane type sesquiterpene B, preparation method thereof and application of guaiane type sesquiterpene B in preparation of tumor prevention and antitumor drugs | |
| CN115286673B (en) | Sesquiterpenoids derived from calix sponge, and extraction method and application thereof | |
| CN114805030B (en) | Diterpenoid component in schizonepeta tenuifolia extract, and preparation method and application thereof | |
| CN115583953B (en) | Quinazolinone alkaloid compound, and preparation method and application thereof | |
| CN111471050A (en) | Staurosporine derivatives and preparation method and application thereof | |
| CN115369137B (en) | Method for extracting adenosine from RAFFAELEA LAURICOLA | |
| CN116903578B (en) | Phenolic acid compound in Glechoma hederacea as well as extraction and separation method and application thereof | |
| CN115043719B (en) | Polyketide from fungus, preparation method and application thereof | |
| CN116375690B (en) | A flavonoid alkaloid compound and its preparation method and application | |
| CN115650946B (en) | Bibenzyl derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |